Appointment purpose
The company develops technology supporting medication reconciliation, prescribing checks, pharmacy workflows, dispensing and administration information. Its outputs can influence care, but they do not remove the authority and responsibility of qualified clinicians and pharmacists. The Board seeks a Director able to govern product trust and commercial scale together.
This mandate centres on three tensions that management must resolve continuously.
Clinical usefulness without unaccountable authority
Define the decisions the software supports, the context it requires, the limitations it displays and the points requiring professional confirmation. Drug identity, strength, form, units, route, frequency, allergies, interactions and patient context must be governed as safety-critical information.
Clinical rules require accountable owners, qualified approval, source rights, update validation, local configuration, retirement and emergency correction. AI features should be assessed by consequence, explainability and error recovery. Aggregate accuracy must not conceal a missed high-risk warning or a dangerous unit conversion.
Connectivity without silent disagreement
Ensure prescribing, pharmacy and administration systems agree on the active order and patient. Review identity matching, duplication, timing, changed orders, reconciliation and downtime. A successful interface transmission is not proof that the receiving workflow acted on the correct version.
Deployment should require workflow assessment, parallel testing, training, release control, rollback and post-launch monitoring. Customer customisation must remain inside defined safety boundaries. Privileged support, emergency access, logs, retention and secondary data use deserve independent scrutiny.
Scale without degraded support
Measure customer contribution after clinical content, implementation, integration, specialist support, infrastructure, security, updates and claims. A product must not scale by reducing the people needed to identify and correct clinical problems. Customer contracts should accurately allocate configuration, source data, professional decisions, response and incident responsibilities.
Matters for independent Board judgment
The Director will challenge new clinical uses, content partnerships, AI capabilities, acquisitions, hospital commitments, international entry and releases with material medication consequence. The Board should see rule corrections, serious incidents, high-risk warning performance, overrides, alert fatigue, interface failures, configuration exceptions, access anomalies, deployment burden and complete margins.
Qualified clinical assurance should test representative patient scenarios, source-to-rule lineage, interface failures, human factors and incident reconstruction. Staff and customer professionals need a protected channel outside commercial management.
Evidence to demand after an incident
- Which product, rule and configuration were active, and which patients or customers may also be affected?
- What did the source systems say at each handoff, and where did the information change?
- What did the user see, understand and do, including overrides and missing context?
- How was the risk contained, communicated and independently reviewed?
- What product, training, contract or monitoring change prevents recurrence?
Director profile and conduct
Candidates should bring at least 22 years across clinical pharmacy, medication safety, informatics, hospital quality, healthcare technology, product governance, cybersecurity, finance or healthcare boards. Suitable backgrounds include clinical or technology executive, pharmacist with enterprise leadership, healthcare CEO, risk officer and Independent Director.
Active inclusion in the IICA Independent Directors Databank is mandatory. Candidates must meet applicable independence and director-eligibility requirements. Relationships with hospitals, pharmaceutical companies, pharmacies, content providers, technology partners, insurers, auditors and investors must be disclosed. The seat may not be used to generate referrals, sales, implementation or consulting work.
The first-year standard is explicit professional authority, controlled knowledge, safer alerts, reliable integrations and growth economics that preserve medication trust. The Director must be prepared to test claims and evidence rather than rely on demonstrations.